Cerus Strategy and Business Model

Executive Overview

Cerus is a commercial-stage blood-safety medical technology company best known for the INTERCEPT platform, which is used to reduce pathogens in blood components before transfusion. Founded in 1991 and headquartered in Concord, California, Cerus operates in the specialized intersection of transfusion medicine, hospital supply, and regulated medical devices. Its core products are used primarily by blood centers, hospitals, and national blood services to treat platelets and plasma; a red-blood-cell version of the platform remains under development. Strategically, Cerus is trying to make pathogen reduction a more routine part of blood safety practice, deepen recurring consumables revenue from its installed base, broaden international adoption, and expand the platform into additional clinical use cases. The company’s value proposition is not simply “better testing”; it is a more proactive approach to reducing transfusion risk from known and emerging pathogens while also inactivating donor leukocytes. Cerus sells in the United States, Europe, the Middle East, and selected other international markets through a mix of direct and distributor channels. By FY2024, Cerus had grown into a just-under-$200 million annual-revenue medtech company, still small by diversified medtech standards but meaningful in its niche.

Cerus at a Glance

Logo
Common name	Cerus
Full legal name	Cerus Corporation
Headquarters	Concord, California, United States
Ownership	Public company; no controlling shareholder disclosed in recent public filings
Ticker	CERS
Exchange	NASDAQ
Market Cap	$518.96M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1991; IPO in 1997; INTERCEPT commercialized first in Europe in the 2000s; U.S. FDA approval for INTERCEPT platelets and plasma in 2014; additional platform expansion in later years including INTERCEPT Fibrinogen Complex-related approval in 2023
Industry or industries	Medical technology, transfusion medicine, blood safety
Key products or services	INTERCEPT Blood System for platelets; INTERCEPT Blood System for plasma; associated illuminators and disposable processing sets; red-blood-cell pathogen reduction system in development
Geographic footprint	United States, Europe, Middle East, and selected Asia-Pacific and Latin American markets
Business segments as officially reported	One operating and reportable segment
Company website	https://www.cerus.com

1. What Is the Strategy of Cerus?

Cerus’s public filings and investor materials describe a focused strategy built around one core idea: make pathogen reduction a more standard part of modern transfusion practice and turn that clinical positioning into a larger, recurring consumables franchise. Using the Playing to Win framework, Cerus’s strategy can be summarized as follows.

1. 1a. What is the winning aspiration of Cerus?

   Cerus’s winning aspiration is to improve blood safety and blood availability by making the INTERCEPT platform a routine part of how blood components are prepared for transfusion. In business terms, winning means more than maintaining a niche product line. It means expanding adoption of pathogen-reduced platelets and plasma, extending the platform into red blood cells over time, and building a stronger recurring revenue base from disposable treatment sets tied to daily blood-processing volumes. Cerus’s public messaging also makes clear that “winning” includes becoming a more profitable and self-sustaining commercial medtech company, not just a science project with good clinical data.

2. 1b. Where does Cerus play?

   Cerus plays in the blood-components portion of transfusion medicine, especially in institutional settings where product safety, regulatory compliance, and workflow reliability matter more than consumer branding. Today the commercial focus is on platelets and plasma. The customer base is concentrated in blood centers, hospitals, health systems, and national blood services. Geographically, Cerus has focused on markets with developed blood infrastructure and regulatory frameworks that can support pathogen reduction adoption, especially the United States and parts of Europe and the Middle East. Over time, the company’s ambition extends to adjacent blood components such as red blood cells, but Cerus is not trying to be a broad hospital-supplies company or a general diagnostics player.

3. 1c. How does Cerus plan to win?

   Cerus plans to win through clinical differentiation and installed-base economics rather than low price. The company’s argument to customers is that pathogen reduction is a proactive safety measure: instead of relying only on testing for specific known threats, INTERCEPT is designed to reduce a broad range of pathogens and inactivate donor leukocytes in treated blood components. That proposition can be especially attractive when new infectious threats emerge, when bacterial-risk requirements tighten, or when customers want to simplify parts of their testing and safety workflow. Once Cerus wins an account, the model can become sticky because the customer validates the process, trains staff, installs equipment, and then repeatedly buys disposable treatment sets. In effect, Cerus is pursuing a medtech “installed base plus recurring consumables” strategy in a highly regulated niche.

4. 1d. What capabilities must Cerus have in place?

   To execute that strategy, Cerus needs a narrow but demanding set of capabilities. The most important are: strong clinical and regulatory capabilities; device and disposable manufacturing under strict quality controls; the ability to support account conversions at blood centers and hospital systems; post-market evidence generation; and reliable supply of validated materials and components. Commercially, Cerus also needs specialized account management, because its buyers are sophisticated institutional decision-makers rather than mass-market purchasers. Finally, Cerus must sustain product-development capability for platform extensions such as red blood cells and next-generation devices.

5. 1e. What management systems does Cerus require?

   Cerus requires management systems typical of a tightly regulated medtech company: robust quality systems, complaint handling and post-market surveillance, clinical-development governance, and disciplined regulatory change control. It also needs strong forecasting and inventory systems because demand can be concentrated in a relatively small number of institutional accounts and because blood-component workflows are time-sensitive. Financially, Cerus needs management systems that track product mix, gross-margin progression, operating expense discipline, and working-capital use, since the company’s path to stronger cash generation depends on scaling commercial volumes while controlling manufacturing and development costs.

2. What Are the Current Strategic Initiatives of Cerus?

Based on Cerus’s recent annual reporting and investor communications, the company’s current strategic agenda has several concrete elements.

• Expand U.S. adoption of INTERCEPT platelets. The United States is one of Cerus’s most important growth markets. A major initiative has been to convert additional blood-center and hospital demand to pathogen-reduced platelets, helped by the fact that platelet safety is a persistent operational and regulatory issue because platelets are stored at room temperature and are vulnerable to bacterial contamination.
• Increase plasma penetration and broaden plasma-related applications. Cerus has been working to deepen use of INTERCEPT-treated plasma and to support additional plasma workflows, including INTERCEPT Fibrinogen Complex-related use cases where approved. This matters because plasma adds volume leverage and expands the platform beyond a single component category.
• Advance the red-blood-cell program. Cerus has continued clinical, regulatory, and manufacturing work on its red-blood-cell pathogen reduction system. This is strategically important because red blood cells are a much larger part of the transfusion market than platelets, but the technical and regulatory burden is also higher.
• Broaden international market access. Cerus continues to pursue growth outside the United States through new registrations, distributor management, and deeper penetration in existing countries. International markets can provide reference sites, diversification, and incremental volume, although adoption patterns vary materially by country.
• Improve manufacturing efficiency and gross margins. As a smaller medtech company, Cerus’s economics are highly sensitive to scale, yields, freight, and product mix. Management has therefore emphasized manufacturing performance, supply reliability, and cost improvement as strategic priorities, not just back-office tasks.
• Build more clinical and economic evidence. Cerus’s commercial motion depends heavily on transfusion medicine evidence, customer education, and workflow adoption. The company therefore continues to invest in data generation, publications, conference visibility, and customer-facing evidence that supports conversion decisions.

3. What Is the Business Model of Cerus?

Cerus has a classic medtech platform model with a strong recurring component.

• What customers actually buy: Customers buy the ability to pathogen-reduce specific blood components as part of their transfusion-preparation workflow. In practice, that means disposable processing sets, illuminators, and related materials, training, and support.
• Recurring versus one-time revenue: The most attractive part of the model is repeat-driven consumables revenue. Every treated platelet or plasma unit requires a new disposable set, so installed accounts can create ongoing demand. Capital equipment revenue from illuminators is more episodic and generally less economically important than the downstream pull-through from disposables.
• Revenue model: This is best understood as a regulated “razor-and-blade” model. Cerus places or sells equipment into customer workflows and then earns recurring product revenue from ongoing use. The company has also had non-core collaboration or contract revenue at times, but the core economics are product-driven.
• How pricing power works: Cerus’s pricing power does not come from consumer branding. It comes from regulatory relevance, clinical differentiation, and workflow stickiness after an account is converted. That said, pricing is still constrained by the budgets of blood centers and hospitals, many of which operate under meaningful cost pressure.
• Why the business mix matters: Profitability depends heavily on the mix between recurring disposables and capital equipment, on the mix between platelet and plasma products, and on geographic mix. Mature recurring accounts are typically more attractive than one-off equipment placements.
• What drives gross margin and operating margin: Gross margin is driven by manufacturing scale, component yields, freight, supply-chain execution, and mix. Operating margin is influenced by gross profit, commercial spending, and R&D expense, especially around the red-blood-cell program.
• What drives cash generation: Cash generation improves when installed-base volumes rise faster than overhead, but it can be pressured by inventory needs, receivables from institutional customers, and continued investment in clinical development and regulatory work.

4. What Products and/or Services Does Cerus Sell?

Cerus sells a relatively concentrated set of products built around the INTERCEPT platform.

• INTERCEPT Blood System for platelets: Cerus’s best-known commercial offering. This system is used by blood centers and other transfusion-service operators to pathogen-reduce platelet components before transfusion.
• INTERCEPT Blood System for plasma: A commercial plasma-treatment offering that extends the platform beyond platelets and gives Cerus a broader role in blood-component safety.
• Illuminators and associated disposables: Cerus provides the hardware and single-use processing sets required to run the INTERCEPT workflow. The hardware helps establish the installed base; the disposable sets are the more recurring part of the revenue stream.
• INTERCEPT Fibrinogen Complex-related applications: These offerings and workflow extensions, where approved, broaden the utility of pathogen-reduced plasma and can deepen customer adoption.
• Red-blood-cell pathogen reduction system in development: This is strategically important but not yet a primary commercial revenue driver. If successfully developed and approved, it would materially expand Cerus’s addressable market.
• Implementation, training, and technical support: Cerus’s commercial model also includes customer onboarding, workflow support, service, and education. In this niche, those services are important even if they are not reported as a large standalone revenue line.

Today, platelets and the associated recurring disposables appear to be the most strategically important commercial driver, with plasma as an important extension and red blood cells as the major longer-term growth option.

5. What Are the Key Competitors or Peers of Cerus?

Cerus operates in a narrow specialty, so the number of direct product-to-product rivals is limited. In practice, Cerus competes not only with other pathogen-reduction technologies but also with substitute approaches such as bacterial detection and blood screening.

The key strategic point is that Cerus’s competitive set is unusual. The company is not fighting dozens of identical rivals; instead, it is often competing against existing clinical practice, alternative safety protocols, and the budget trade-offs of hospitals and blood centers.

6. What Is the Marketing Strategy of Cerus?

Cerus’s marketing strategy is evidence-led, account-focused, and highly specialized. This is not a consumer brand or broad-reach digital-marketing story. Cerus sells into a technical clinical environment where physicians, transfusion specialists, blood-center operators, and procurement leaders all matter.

• Clinical evidence marketing: Published data, hemovigilance results, safety evidence, and workflow outcomes are central to the message. Cerus has to persuade clinical and operational stakeholders, not just buyers.
• Account-based commercial support: Large blood centers and hospital systems require targeted engagement, implementation planning, and economic justification. That makes Cerus’s marketing closely tied to the sales process.
• Conference and key-opinion-leader engagement: Industry meetings in transfusion medicine are important because peer validation and scientific visibility strongly influence adoption.
• Market-access and workflow education: Cerus must explain not only why pathogen reduction matters clinically, but also how it changes workflows, compliance approaches, and budget trade-offs.

Brand marketing matters, but mainly as a trust signal around INTERCEPT. The deeper differentiator is not advertising; it is clinical credibility backed by implementation support.

7. What Are the Key Customer Segments of Cerus?

Cerus’s customer base is institutional and relatively concentrated compared with most healthcare companies.

• Blood centers and blood collection organizations: These are among Cerus’s most important direct customers because they process blood components at scale and can drive recurring consumables demand.
• Hospitals and health systems: Hospitals are important as both direct customers in some cases and as downstream users of pathogen-reduced components. Hospital demand helps determine blood-center adoption.
• National blood services and public-sector transfusion systems: In some countries, national or quasi-public systems can make country-level decisions that materially affect adoption.
• Government and military-related channels: These are smaller but strategically relevant where preparedness, emerging pathogen risk, or trauma care create interest in advanced blood safety.
• Distributors and channel partners: In smaller or less directly served markets, distributor relationships matter because they expand Cerus’s reach without requiring a full direct commercial footprint.

Cerus is not a diversified end-market story in the way a broad medtech supplier is. Its fortunes are tied closely to transfusion medicine and to a relatively small number of sophisticated institutional accounts.

8. What Is the Sales Model of Cerus?

Cerus uses a specialized business-to-business sales model built around direct institutional selling, technical support, and selective distributor coverage.

In core markets, especially the United States, Cerus sells through a direct commercial organization that works with blood centers, hospitals, and health-system stakeholders. The sale is typically consultative rather than transactional. Customers must understand the clinical rationale, validate the workflow, train staff, and often integrate the system into existing operating procedures before volumes scale.

In smaller or more fragmented international markets, Cerus supplements its direct reach with distributor and channel-partner relationships. That allows the company to broaden geographic coverage without building a full-country infrastructure everywhere.

The channel structure matters strategically:

• Growth: Large-account wins can move revenue meaningfully because volumes are concentrated.
• Pricing: Direct relationships support value-based selling, while distributor markets may trade some intimacy for reach.
• Customer stickiness: Once an account has validated the INTERCEPT workflow and installed equipment, recurring consumables demand can become durable.
• Consultant opportunity: Because the model involves long conversion cycles, channel design, account prioritization, sales-force deployment, and distributor management are all areas where external expertise can help.

9. In What Geographies Does Cerus Operate?

Cerus operates internationally, but not with the breadth of a large diversified medtech company. Its footprint is focused on markets where blood infrastructure, regulation, and customer economics can support pathogen reduction.

• United States: The U.S. is strategically central because of its scale, the importance of platelet safety protocols, and the concentration of blood-center accounts. Cerus’s corporate headquarters are in Concord, California, and the company’s U.S. commercial, corporate, and important operational functions are centered there.
• Europe: Europe has long been important to Cerus as a commercial and reference market. Adoption patterns vary by country, but European use has been a key part of the company’s installed base and clinical credibility.
• Middle East: Cerus has also participated in selected Middle Eastern blood-safety markets, typically through a mix of direct and partner-supported approaches.
• Selected Asia-Pacific and Latin American markets: Cerus serves some additional markets through registrations and distributors rather than building full direct infrastructure in every country.

Operationally, Cerus is more concentrated than global mega-cap medtech peers. That concentration has advantages and disadvantages: it allows focus in a specialized category, but it also means growth can be meaningfully affected by regulatory and commercial developments in a relatively small number of countries and accounts.

10. Who Are the Owners of Cerus?

Cerus is a publicly traded company listed on Nasdaq under the ticker CERS. As of recent proxy and beneficial-ownership disclosures, Cerus does not appear to have a controlling shareholder. Ownership is spread across institutional investors, index funds, specialist small-cap and healthcare investors, insiders, and retail shareholders. That means Cerus is governed more like a conventional public small-cap medtech company than a founder-controlled or private-equity-controlled business.

11. How Is Cerus Organized?

Cerus is organizationally simpler than many medical technology companies because it is built around one core platform and, as recently reported, one operating and reportable segment.

• Commercial organization: Sales and market-development teams are oriented around geographic markets and key institutional accounts.
• Operations: Manufacturing, supply chain, quality, and service functions support the delivery of devices and disposable sets into regulated customer workflows.
• Clinical, regulatory, and R&D: These teams are central because Cerus’s business depends on evidence generation, product approvals, and lifecycle management.
• Corporate functions: Finance, legal, and public-company infrastructure sit over a relatively focused operating model.

Practically, Cerus behaves less like a conglomerate and more like a focused platform company: one flagship brand, one core science base, one narrow set of customer workflows, and a limited number of high-stakes growth programs.

12. How Does Cerus Operate?

Cerus operates by embedding its technology into the blood-component preparation process. Day to day, the business is not simply about shipping products; it is about supporting a highly regulated clinical workflow.

1. Manufacture and supply: Cerus produces or coordinates production of the disposable sets, device components, and related materials needed for the INTERCEPT workflow.
2. Install and validate: Blood centers and other customers install or deploy Cerus equipment and validate the workflow under their own operational and quality procedures.
3. Treat blood components: The customer uses the INTERCEPT process to treat platelets or plasma before the component is released for use.
4. Distribute treated components: Once processed, those components move through the normal blood-distribution channel to hospitals and clinical end users.
5. Support, replenish, and monitor: Cerus provides ongoing technical support, service, training, regulatory documentation, and replenishment of consumables.

The operational complexities are meaningful. Blood components are time-sensitive. Customer forecasting can shift with hospital demand. Manufacturing changes must be tightly controlled. And because Cerus serves a niche but mission-critical clinical workflow, reliability matters at least as much as product innovation.

13. What Are the Growth Opportunities for Cerus?

The most plausible growth opportunities for Cerus, based on management priorities and industry logic, are the following.

• Higher U.S. platelet penetration: This is likely the clearest commercial opportunity. The U.S. market is large, technically sophisticated, and sensitive to platelet safety and compliance requirements.
• Deeper plasma adoption: Plasma gives Cerus another way to leverage the installed base and improve customer economics.
• Red-blood-cell expansion: If Cerus can successfully advance and commercialize its red-blood-cell program, the addressable market would expand significantly. This is the biggest strategic upside but also the most execution-heavy opportunity.
• International country expansion: New registrations, targeted distributor improvements, and deeper penetration in existing countries can add growth without requiring Cerus to reinvent its platform.
• New applications built around existing plasma workflows: Additional use cases such as INTERCEPT Fibrinogen Complex-related applications can deepen platform utility at existing accounts.
• Margin-led growth: Better manufacturing economics, improved product mix, and greater installed-base utilization can increase earnings quality even if headline revenue growth remains moderate by software standards.

Main constraints include regulatory timelines, customer budget pressure, adoption-cycle length, manufacturing scale-up discipline, and the fact that alternative blood-safety methods remain entrenched in many markets.

14. What Is the History of Cerus?

Cerus was founded in 1991 in California by Dr. Laurence Corash and colleagues with a focus on pathogen inactivation technologies for blood safety. The company went public in 1997, giving it access to capital for a long development cycle in a technically demanding and highly regulated niche.

In the 2000s, Cerus began commercializing INTERCEPT in Europe, where the company established early clinical and operational experience. A major milestone came in 2014, when the U.S. Food and Drug Administration approved INTERCEPT for platelets and plasma, opening the path to broader U.S. commercialization. In later years, Cerus continued to extend the platform through additional product and indication work, including progress in plasma-related applications and ongoing development of a red-blood-cell system.

One notable feature of Cerus’s history is that it has been built largely through organic technology development and commercialization rather than through a roll-up strategy. It is not known primarily for major acquisitions or large portfolio reshaping. Instead, its history is the story of a focused company trying to turn a long-developed blood-safety platform into a larger commercial franchise.

15. What Are the Key Suppliers to Cerus?

Suppliers matter materially to Cerus because its products are regulated, validated, and used in clinically sensitive workflows. Cerus has disclosed in its public filings that it depends on limited or single-source supply for some materials and components, which is common in specialized medtech.

• Critical chemical and biological inputs: The INTERCEPT workflow relies on specialized validated inputs, including the active photochemical components used in treatment.
• Disposable-set materials and components: Plastics, sterile packaging, filters, and related single-use elements are essential because each treated unit requires new consumables.
• Device and illuminator components: Cerus depends on hardware parts and manufacturing partners for the equipment side of the platform.
• Contract manufacturing and sterilization partners: These partners can be strategically important because they sit inside a regulated production chain where switching is not trivial.
• Logistics and distribution providers: On-time delivery matters because blood-safety workflows are operationally sensitive, even if Cerus is not shipping a consumer product.

Supplier structure matters strategically because a change in source, material, or process may require revalidation and, in some cases, regulatory review. That makes dual sourcing and supply assurance more complex than in many less regulated industries.

16. What Are the Key Brands Owned by Cerus?

Branding is important to Cerus, but in a clinical trust-and-evidence sense rather than in a mass-market sense. The company’s brand architecture is concentrated.

• INTERCEPT: This is Cerus’s core umbrella brand and the center of its commercial identity. In the market, INTERCEPT stands for pathogen reduction in blood components.
• INTERCEPT Blood System for Platelets: The company’s flagship commercial offering and the most visible sub-brand in daily transfusion practice.
• INTERCEPT Blood System for Plasma: An important extension that broadens the platform beyond platelets.
• INTERCEPT-related plasma applications, including INTERCEPT Fibrinogen Complex: These extend the reach of the brand into additional clinical workflows where approved.
• INTERCEPT Blood System for Red Blood Cells: Strategically important as a development-stage brand extension, even though it is not yet the primary commercial engine.

Cerus is therefore a one-brand-platform company more than a house of many brands. That can be an advantage because commercial investment, evidence generation, and customer recognition all reinforce the same umbrella identity.

17. How Does the Supply Chain of Cerus Function?

Cerus’s supply chain is a regulated medtech supply chain built around validated materials, device assembly, sterile manufacturing steps, and dependable delivery into institutional healthcare settings.

1. Sourcing: Cerus procures specialized chemicals, device parts, plastics, packaging, and other validated inputs from a relatively narrow supply base.
2. Manufacturing and assembly: Products are manufactured internally and through partners, depending on the component and process step.
3. Sterilization, quality release, and regulatory documentation: These steps are essential because Cerus products sit inside blood-processing workflows where quality failures are unacceptable.
4. Inventory and fulfillment: Cerus must balance service levels with working-capital discipline. Too little inventory risks customer disruption; too much inventory ties up cash.
5. Field installation and replenishment: The supply chain does not end at shipment. Equipment deployment, consumable replenishment, and service continuity all affect customer retention.

Supply-chain reliability is strategically important because Cerus’s customers are often processing blood components on tight schedules. In this context, resilience and compliance can matter as much as unit cost.

18. What Is the Technology Strategy of Cerus?

Cerus’s technology strategy centers on photochemical pathogen reduction and the device-and-consumables ecosystem needed to make that science usable in routine blood processing. This is not a general-purpose digital platform strategy. The technology that matters most is embedded in the clinical product.

• Customer-facing technology: The core technology is the INTERCEPT treatment process itself, including the chemistry, illumination system, disposables, and workflow design.
• Platform extension: Cerus’s technology roadmap appears aimed at broadening the platform across additional blood components and improving ease of use and manufacturing economics.
• Evidence as a technology asset: In Cerus’s category, clinical data and regulatory know-how are part of the technology moat. A scientifically elegant system without validation and evidence would not be commercially powerful.
• Internal enablement: Behind the scenes, quality systems, service support, and manufacturing process control are important technology enablers even though they are not the product customers see.

In short, Cerus’s technology strategy is about maintaining a defendable scientific platform, improving workflow fit, and converting that platform into more routine use in transfusion medicine.

19. What Is the R&D Strategy of Cerus?

R&D is central to Cerus because the company’s growth options depend on platform extension as much as on commercial execution. Cerus is not a mature “harvest the installed base” company; it still needs development success to enlarge its addressable market.

• Advance the red-blood-cell program: This appears to be the most important development initiative because it could open the largest incremental market opportunity.
• Support lifecycle improvements: R&D also includes improvements to devices, consumables, and workflow efficiency that can lower cost or improve usability.
• Expand evidence and indications: In Cerus’s market, R&D does not stop at lab innovation. Clinical studies, regulatory submissions, and post-market evidence are part of the development engine.
• Protect platform relevance: Continued investment helps Cerus respond to changing standards, new pathogen concerns, and evolving customer expectations.

For Cerus, good R&D is not only about scientific novelty. It is about translating a complex technology into approved, manufacturable, economically viable products that blood centers can adopt at scale.

20. What Is the Finance Strategy of Cerus?

Cerus’s finance strategy is shaped by its position as a focused, still-scaling public medtech company. The company is not managed for dividends or buybacks. Its financial priorities are to fund growth, support the installed base, advance development programs, and improve margins and cash generation over time.

• Reinvest in commercial expansion: Capital is directed toward sales support, market access, and account conversion in core markets.
• Fund R&D selectively but meaningfully: The red-blood-cell program and platform extensions require sustained spending, so Cerus has to balance innovation with operating discipline.
• Improve gross margin: Manufacturing scale, product mix, and supply-chain efficiency are important financial levers because they influence the speed at which revenue growth translates into profit improvement.
• Manage working capital carefully: Inventory and receivables matter for a company of Cerus’s size, especially in a business with concentrated institutional accounts and regulated supply requirements.
• Maintain liquidity flexibility: Small-cap medtech companies need enough financial flexibility to absorb regulatory delays, demand timing shifts, and development costs without disrupting strategy.

In practical terms, Cerus’s finance strategy exists to bridge the company from a smaller-scale commercial platform to a more profitable, more self-funded operating model.

21. How Companies Like Cerus Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like Cerus use Umbrex when they need top-tier strategic, operational, commercial, finance, ERP, or AI talent for a focused project, but do not need the cost and overhead of a full consulting team. For a specialized medtech company like Cerus, the best consultant projects are usually tightly scoped, data-driven, and closely tied to adoption, operations, and margin improvement.

• U.S. platelet growth strategy: Prioritize target blood centers and hospital systems, estimate conversion potential, and build an account-by-account expansion roadmap.
• Value proposition and pricing architecture: Refresh the economic case for INTERCEPT versus alternative safety workflows, including price corridor analysis and customer-segment-specific value messaging.
• International market prioritization: Rank countries by regulatory readiness, distributor quality, reimbursement logic, and addressable volume to guide expansion sequencing.
• Red-blood-cell commercialization readiness: Design launch scenarios, target-customer archetypes, manufacturing-readiness requirements, and go-to-market models for a future red-blood-cell rollout.
• Gross-margin improvement program: Identify cost-down opportunities across manufacturing, sourcing, logistics, and product mix without compromising regulated quality requirements.
• Supplier-risk and dual-sourcing strategy: Map single-source exposures, qualification pathways, and inventory buffers for critical components and contract manufacturing steps.
• Sales-force effectiveness and key-account management: Redesign territory coverage, clinical specialist deployment, and account-conversion playbooks for concentrated institutional customers.
• Distributor strategy and channel governance: Improve partner selection, incentives, performance metrics, and market-development support in non-core countries.
• Sales and operations planning: Build a more rigorous demand-planning and inventory-management process suited to a regulated medtech business serving time-sensitive blood workflows.
• ERP, data, and AI-enabled decision support: Develop dashboards and forecasting tools for account demand, field service, margin tracking, and supply-chain visibility across a relatively concentrated installed base.